Vasogen Inc (NYSE:MEW - TSE:VAS) Immune Modulation Therapies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasogen Inc (NYSE:MEW - TSE:VAS) Immune Modulation Therapies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nikole Wollerstein who wrote (11)	9/13/2001 11:37:32 AM
From: tuck	Read Replies (1) of 26

>>TORONTO, Sept. 13 /PRNewswire/ - William R. Grant, Chairman, and David Elsley, President and CEO of Vasogen Inc. (TSE:VAS - news; AMEX:MEW - news) today stated that there are no corporate developments that would account for the recent change in the Company's stock price. They further stated that the Company continues to achieve its planned milestones, and that Vasogen's outlook remains both positive and consistent with that communicated to shareholders during its second quarter conference call held July 25th, 2001. Vasogen is focused on developing immune modulation therapies for the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies are designed to target fundamental disease-causing events, providing safe, effective treatment.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next